GSK’s Q3 Sales Dip on Vaccine Slump, but Specialty Medicines Drive Growth

GlaxoSmithKline (GSK) reported a mixed bag of results for the third quarter, with sales coming in slightly below analyst expectations due to a slump in vaccine revenue. The company recorded $10.42 billion in sales, down 2% year-over-year, but up 2% on a constant currency basis. Analysts had anticipated sales of $10.78 billion.

The decline in sales was primarily attributed to a significant drop in vaccine revenue, which fell 18% (or 15% at constant currency) to 2.65 billion pounds. GSK attributed this decline to a combination of factors, including:

*

Changes in ACIP Guidelines:

The Advisory Committee on Immunization Practices (ACIP) revised its guidelines for certain vaccines, impacting sales of Arexvy, a shingles vaccine.
*

Prioritization of COVID-19 Vaccinations:

The ongoing focus on COVID-19 vaccinations has led to reduced demand for other vaccines.
*

Lower Seasonal Infections:

Lower seasonal infection rates have contributed to a decrease in vaccine demand.
*

Tough Comparators:

The company faced tough comparisons due to strong initial stockpiling of Arexvy last year.

Despite the decline in vaccine sales, GSK’s specialty medicine division saw strong growth, increasing by 14% to 2.97 billion pounds. This growth was driven by robust performances in the company’s HIV drugs and oncology therapies.

GSK’s HIV drug revenues grew by 8% to 1.75 billion pounds, while General Medicines sales rose by 3% to 2.39 billion pounds. The company highlighted the strong performance of Trelegy, its asthma drug, which saw sales reach 600 million pounds, up 12% year-over-year.

Despite the mixed results, GSK maintained its positive outlook for 2024, reaffirming its adjusted EPS growth forecast of 10% to 12%. The company also expects core operating profit to increase by 11% to 13% and sales to expand by 7% to 9%.

However, GSK did adjust its outlook for vaccine sales, now projecting a decrease in the low-single-digit percentage compared to earlier guidance of an increase in the low to mid-single-digit percentage. The company expects strong growth in its specialty medicine division, with revenue projected to increase by a high-teens percentage compared to a prior growth range of mid-to-high teens percent. GSK forecasts General Medicines sales to rise at a mid-single-digit percentage compared to earlier guidance of low to mid-single-digit percent.

While GSK stock was down 4.69% to $36.38 during the premarket session, the company’s reaffirmation of its 2024 financial guidance and its continued investment in high-growth specialty medicines suggests a positive long-term outlook for the company.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top